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infusions. All 5 patients with absence of B cell function had
less than 25% B cell donor engraftment and 3 of them had
received ablative conditioning. Less than 25% donor B cell
engraftment correlated with abscense of function (P ¼
.006). 4/5 patients with absent B cell function have IL2RG
genetic defect (OR¼5.12, P ¼ .038). All the recipients of
MMUCB achieved faster and more reliable B cell function
compared to other donor sources (P ¼ .003). Hence absence
of adequate B cell function is most closely associated with
pts who have IL2RG defect irrespective of conditioning. In
addition, donor source inﬂuence the speed and probably
the ultimate success of B cell engraftment (MMUCB>haplo
donors).186
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TKIs are known to affect T and NK cells. We therefore
assessed immunological reconstitution and function in 24
pts with advanced CML and Ph+ ALL who received Nicotinib
as maintenance therapy post alloSCT (study CAM-
N107AIL03T). At 6 months after alloSCT, 11 of 15 pts with
advanced CML had attained CCyR, 11 of 15 pts with advanced
CML had attained a MMR or better, and 5 of 7 pts with Ph+
ALL attained a CR. The median OS was 16 months, with
predicted 1- and 2- year rates of 55% (95% CI, 32% e 72%) and
50% (95% CI, 28%e 68%), respectively. The median PFS was 11
months, with predicted 1- and 2- year rates of 50% (95% CI,
28% e 68%) and 38% (95% CI, 17% e 59%), respectively.
Immunological testing was performed pre- and post Niloti-
nib maintenance therapy in 12 pts in this study. The relative
percentage of T- lymphocyte subsets (assessed by FACS) and
total lymphocytes number were stable during Nilotinib
maintenance therapy, while a 7.82.5 fold increase in B cells
was noted. T cell mitogenic response with aCD3 and PHA
(stimulation index ratio) was sustained (2.51.0, vs. 2.81.05
and 3.31.3 vs. 5.32.9 stimulation. Mean thymic output
determined by TREC quantiﬁcation pre-, during and post
Nilotinib administration was 81.8108, 81.290.3 andTable
3 Months after dUCBT
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
WBC 5900.0 4850.0 0.377
CD3+ count 10.6 50.0 0.097
% CD3+ of lymphocytes 2.55% 11.00% 0.066
Richness Alpha Diversity 585 3905
Clonality 1-Normalized
Entropy
0.1381 0.2454 0.090
Total Repertoire Overlap Index
Persistence of Top 10 Clones142.8197.4 copies per 0.5ug DNA indicating continuous
thymopoiesis. Similarly, no signiﬁcant change of the TCR
repertoire was observed during Nilotinib treatment. Normal
expression of the TCR repertoire was detected in 15.15.5
and 15.35.6 of the examined TCRs. NK cytotoxic activity
against K562 expressed as fold of change from baseline, also
remained stable during Nilotinib treatment (2.81.1 and
2.30.8, respectively). In summary, Nilotinib maintenance
therapy post alloSCT in pts with advanced CML and Ph+ALL
did not interfere or jeopardized immune reconstitution and
function.187
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In double umbilical cord blood (UCB) transplantation
(dUCBT), ex vivo modulation of a single UCB unit with 16,
16 dimethyl prostaglandin E2 (dmPGE2) accelerates
neutrophil engraftment and leads to preferential hemato-
poietic dominance with complete T cell chimerism as early
as 13 days from dUCBT. We sought to determine whether
dmPGE2 affected the recovery of T cell diversity after
dUCBT.
Methods: dUCBT recipients received ﬂudarabine, melphalan,
and ATG conditioning with Tacrolimus and Sirolimus GvHD
prophylaxis. TCRb CDR3 regions were ampliﬁed and
sequenced using the ImmunoSeq assay (Adaptive Biotech-
nologies) from a median of 171 ng of T cell gDNA (range 0.8 -
400.0 ng) at 3 and 12 months from dUCBT. We analyzed 5
paired samples with dmPGE2-dominance (PD); 3 paired and
7 single 12 month untreated (U) samples; and 5 paired and 1
single 12 month dmPGE2 treated sample with untreated-
dominance (UD). The U+UD groups were combined as one
control cohort.
Results: PD CD3+ cells were lower at 3 months versus the
U+UD group (P ¼ .057, Table) but this trend diminished by 12
months (P ¼ .11). Lower CD3+ counts were reﬂected in lower
total TCR alpha diversity in PD samples at both time points (3
month median 585 vs. 3905 unique TCR sequences, P ¼ .079;12 Months after dUCBT
P value -
U test
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
P value -
U test
1 4300.0 6500.0 0.049 0.035
0.26 159.4 444.2 0.016 0.014
0.057 12.30% 31.85% 0.161 0.11
0.079 2729 12062.5 0.22
0.19 0.1105 0.2326 0.945 0.54
0.0873 0.3884 0.027 0.057
2 10 0.040
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P ¼ .22). Median lymphocyte counts did not increase
between 3 and 12 months in the PD group as in the U+UD
group, but the proportion of CD3+ cells within lymphocytes
increased in both groups. PD T cell repertoires were less
clonal than U+UD samples at 3 months (1-normalized
entropy: 0.14 vs. 0.25, P ¼ .09) and 12 months (1-normalized
entropy: 0.11 vs. 0.23, P ¼ .95), with more even frequency
distribution of TCRs. PD T cell repertoire was more dynamic
than the U+UD controls with a signiﬁcantly decreased T cell
clonal persistence between 3 and 12 months (TCR sequence
overlap: 8.73% vs. 38.84%, P ¼ .027).
Conclusions: Ex vivo dmPGE2 modulation with dmPGE2
dominance results in delayed Tcell and lymphocyte recovery,
but less clonality despite a T cell repertoire restricted by low
CD3+ counts. The reduced oligoclonality and rapid T cell
turnover may indicate enhanced thymopoiesis. Correlation
with TRECs and clinical infectious outcomes is ongoing.
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CMV reactivation after allo-SCT is usually monitored by
CMV-PCR. We present the results of a pilot study looking at
the additional use of Multimers for monitoring CMV-speciﬁc
CD8+ T-cells at different intervals after allo-SCT.
10 patients (4 males) that underwent allo-SCT from HLA-
identical siblings (n¼4) or HLA-matched unrelated (n¼6)
donors between May 2010 and May 2012 were enrolled. The
diagnosis was acute leukemia (n¼6), lymphoproliferative
disorders (n¼2) and myelodysplastic syndromes (n¼2). All
patients and 8 donors were CMV seropositive. All patients
were positive for the HLA-A*0201 allele. Pentamers (Proim-
mune, UK) and Streptamers (Gottingen GmbH, Germany)
were directed against the epitope NLVPMVATV of the
pp65495-503 protein of CMV in the context of HLA-A*0201.
Samples were obtained from engraftment at 30-day intervals
until day +180 and 2-monthly thereafter.
The median follow-up was 12.6 (4-21) months after SCT.
Engraftment occurred in all patients at a median of 21.2 (15-
27) days. Acute GVHD was diagnosed in 4 patients at
a median of 63.3 (25-92) days. One patient developed acute
GVHD following infusion of donor lymphocytes for the
treatment of mixed chimerism on day +323.
Three patterns were observed. In 2 patients no CMV-
speciﬁc CD8+ T-cells could be detected after SCT despite
several episodes of CMV-PCR reactivation requiring pro-
longed antiviral treatment. In 5 patients CMV-PCR reac-
tivation triggered a rapid increase of CMV-speciﬁc CD8+
T-cells (median 112.2 x 105/L, range 1.3-279.7 x 105/L).
However, the CMV-PCR became immediately negative and
antiviral treatment was stopped in all reactivations within 2
weeks. Subsequent CMV-PCR reactivations also lasted under
2 weeks in this group. Finally, 3 patients showed an early
immune reconstitution with CMV-speciﬁc CD8+ T-cells
detected (median 1.3 x 105/L, range 0.3-2.3 x 105/L) at
a median of 21 (17-33) days post-SCT. No CMV-PCR reac-
tivation was observed in this group.
We conclude that monitoring CMV-speciﬁc T-cell immu-
nity after allo-SCT in combination with CMV-PCR may be
able to distinguish patients at higher risk of CMV reactivationand in need of prolonged antiviral therapy. Patients with
CMV-speciﬁc CD8+ T-cells detectable at the time of CMV-PCR
reactivation may only need a short course of antiviral
therapy, while those with early and persistent CMV-speciﬁc
CD8+ T-cells may be at a very low risk of developing CMV
disease in the long-term.189
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Recent studies show that accelerated gd T cell reconsti-
tution after hematopoietic stem cell transplantation (HSCT)
is associated with improved overall survival (OS) though the
mechanisms have not been elucidated. We evaluated 102
consecutive pediatric patients with acute leukemia under-
going HSCT at St. Jude Children's Research Hospital from
1996-2011. Themedian age of the patients was 10.5 5.9 yrs.
(range, 0.6-25.2) and median follow up was 2.71.8 yrs.
(range 0.2-6.0). There were 57% males, 43% females and 59%
with ALL and 41% with AML. There were 14 patients with
elevated gd T cells (1.75x105 cells/ml) and 88 with low/
normal gd T cells (<1.75x105 cells/ml). There were no
signiﬁcant differences between the two groups with respect
to age, sex, disease or donor source, p¼0.7, 0.5, 1 and 0.07
respectively. Fours years after HSCT, Overall Survival (OS)
was signiﬁcantly higher for patients in the elevated group
compared to the patients in the low/normal group, 93% and
60%, respectively, p¼0.0173. Survival without relapse or graft
failure, Event Free Survival (EFS), was signiﬁcantly higher in
the elevated group compared to the low/normal group, 85.7%
and 58.0%, respectively. Since T cell reconstitution following
HSCT is age dependent, we determined if gd T cell recovery
correlated with age and/or CD3+ cells. Multivariate analysis
showed no correlation between the number of CD3+ and gd T
cells. In fact, 13 of 14 patients that recovered with increased
number of gd T cells had normal or low numbers of CD3+
cells. Thus, gd T cell recovery is not a simple correlate of T cell
reconstitution. Because gd T cells play a central role in
maintaining intestinal epithelium integrity, we evaluated the
incidence of gut GVHD. We found a signiﬁcant lower rate of
gut GVHD in the elevated group compared to the low/normal
group, 0% and 17% respectively. Furthermore, the number of
gd T cells in patients with cGVHD (2.3 x105 cells/ml) was
signiﬁcantly lower compared to patients without cGVHD (6.2
x105 cells/ml), p¼0.01. This suggests that gd T cell may
protect against gut and cGVHD. Since accumulating evidence
suggests that gd T cells contribute to both innate and adap-
tive immune responses during infections, we evaluated the
rate and types of infection between the two groups. We
found a signiﬁcant lower incidence of infections reported
in the elevated group compared to the low/normal group,
21% and 54% respectively p¼0.02. Furthermore, the elevated
group had only viral infections while the low/normal group
had viral, bacterial and fungal infections. In summary, this is
the ﬁrst reported study of gd T cell recovery after HSCT in
pediatric patients and adds new insights into the role gd T
